echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Kangfang Bio-PD-1 submitted the US listing application: being selected for RTOR, faster than priority review

    Kangfang Bio-PD-1 submitted the US listing application: being selected for RTOR, faster than priority review

    • Last Update: 2021-06-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 24, 2021, Kangfang Bio-Bio announced that the PD-1 antibody AK105 was selected for the FDA's real-time tumor review (RTOR) new policy, and it has initiated the BLA application for third-line nasopharyngeal carcinoma.


    In addition to Hengrui Pharmaceuticals, the first echelon of domestic PD-1 has completed the blockbuster license-out transaction.


    to sum up

    In March 2021, Junshi Biologics submitted a rolling listing application for PD-1 antibody (nasopharyngeal cancer) to the FDA.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.